Form 4 for TXMD TherapeuticsMD, Inc.
Accepted 2023-04-14 00:00:00 ET · period of report 2023-04-12 · accession 0001209191-23-024388 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-14 | 2023-04-12 | TXMD | Walker Marlan D | CEO | S - Sale+OE | $3.65 | -1,170 | 12.3K | -9% | -$4,270 |
| DM | 2023-04-14 | 2023-04-12 | TXMD | Walker Marlan D | CEO | M - OptEx | $0.00 | +7,508 | 8,999 | +504% | $0 |
| DM | 2023-04-14 | 2023-04-12 | TXMD | Walker Marlan D | CEO | M - OptEx | $0.00 | -7,508 | 3,466 | -68% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-12 | S | D | 1,170 | $3.65 | 12,307 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $3.63 through $3.71, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. |
| 2 | Common | Common Stock | 2023-04-12 | M | A | 1,734 | $0.00 | 13,477 | D | — | — | |
| 3 | Common | Common Stock | 2023-04-12 | M | A | 1,734 | $0.00 | 11,743 | D | — | — | |
| 4 | Common | Common Stock | 2023-04-12 | M | A | 1,010 | $0.00 | 10,009 | D | — | — | |
| 5 | Common | Common Stock | 2023-04-12 | M | A | 3,030 | $0.00 | 8,999 | D | — | — | |
| 6 | Derivative | Performance Stock Units | 2023-04-12 | M | D | 3,030 | $0.00 | 0 | D | $0.00 · — to — | 3,030 Common Stock | (F3) The performance stock units (PSUs) vested upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs would have been forfeited. Each PSU represents a contingent right to receive one share of common stock of the issuer. |
| 7 | Derivative | Restricted Stock Units | 2023-04-12 | M | D | 1,010 | $0.00 | 0 | D | $0.00 · — to — | 1,010 Common Stock | (F4) Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023. |
| 8 | Derivative | Restricted Stock Units | 2023-04-12 | M | D | 1,734 | $0.00 | 3,466 | D | $0.00 · — to — | 1,734 Common Stock | (F5) Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. |
| 9 | Derivative | Performance Stock Units | 2023-04-12 | M | D | 1,734 | $0.00 | 3,466 | D | $0.00 · — to — | 1,734 Common Stock | (F6) The vested performance stock units (PSUs) represent PSUs deemed by the compensation committee to be vested at target due to the change in the issuer's business model. The remaining PSUs vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023. One quarter of the initial PSUs were forfeited based on the failure of the issuer to achieve certain EBITDA milestones for the year ended December 31, 2021. Each PSU represents a contingent right to receive one share of common stock of the issuer. |